Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC38H49ClN8O5S2 |
InChIKeyBOGSCFVLWKIZLK-AWCRTANDSA-N |
CAS Registry2853543-24-3 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Preclinical | United States | 19 Oct 2022 |